We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Generalized Anxiety and Seroquel (GAD)

This study has been terminated.
(The underwriter stopped the funding)
Sponsor:
ClinicalTrials.gov Identifier:
NCT01066143
First Posted: February 10, 2010
Last Update Posted: May 17, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Igor Elman, MD, Mclean Hospital
  Purpose
The 12 week clinical trial of Seroquel in Generalized Anxiety Disorder (GAD) patients will be combined with fMRI experiments.

Condition Intervention
Generalized Anxiety Disorder Seroquel XR Drug: Seroquel XR

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pharmacotherapy of Generalized Anxiety Disorder With Seroquel: Normalization of Brain Stress and Reward Function

Resource links provided by NLM:


Further study details as provided by Igor Elman, MD, Mclean Hospital:

Primary Outcome Measures:
  • Change From Baseline in GAD Symptomatology at the Week 12 Timepoint. [ Time Frame: 12 week ]
    Changes in anxiety symptomatolgy


Enrollment: 8
Study Start Date: February 2010
Study Completion Date: February 2013
Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Seroquel XR Drug: Seroquel XR
Seroquel XR tablets will be flexibly dosed and begun at a target dose of 50 mg on day 1, 100 mg on day 2, 150 mg on day 3 and 200 mg on day 4 with a maximal daily dose of 400 mg on subsequent days.

Detailed Description:
Subjects will be recruited from clinic patients and known research subjects at McLean Hospital, as well as by advertisements in the media, flyers, and word of mouth. An initial telephone interview will be conducted to determine if potential subjects meet the basic study requirements. Subjects will be also screened for drug use. If no obvious health problems are present, subjects will be scheduled for an evaluation. Upon arrival at the research unit, each subject will first complete a standardized interview schedule designed to obtain personal and background data such as age, marital status, socio-economic status, education, employment, etc. The Research Assistant will give subjects both verbal and written descriptions of the study procedures. After briefing subjects on the reasons for the research, subjects will be given the opportunity to ask questions. When they are ready, subjects will be asked to sign the written informed consent form approved by the Mclean Institutional Review Board (IRB). Functional magnetic resonance imaging scans to examine brain functioning will be obtained from GAD patients (N=30) at baseline and after 12 weeks. Seroquel XR tablets will be flexibly dosed and begun at a target dose of 50 mg on day 1, 100 mg on day 2, 150 mg on day 3 and 200 mg on day 4 with a maximal daily dose of 400 mg on subsequent days.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Provision of written informed consent
  • Fluency in English
  • A diagnosis of GAD
  • No pregnancy
  • Right-handedness
  • Psychotropic medication-free at the start of the study

Exclusion Criteria:

  • Pregnancy or lactation
  • Any current DSM-IV-TR Axis I disorder
  • Any mental retardation or cognitive impairment that precludes informed consent
  • Known intolerance or lack of response to quetiapine fumarate
  • Substance or alcohol dependence at enrollment
  • Participation in another drug trial within 4 weeks prior enrollment
  • History of allergic reaction or hypersensitivity to Seroquel or Seroquel XR
  • History of prior Seroquel or other antipsychotic agents use
  • Contraindications to magnetic resonance imaging
  • Treatment with an effective medication for GAD
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01066143


Locations
United States, Massachusetts
McLean Hospital
Belmont, Massachusetts, United States, 02478
Sponsors and Collaborators
Mclean Hospital
  More Information

Responsible Party: Igor Elman, MD, MD, Mclean Hospital
ClinicalTrials.gov Identifier: NCT01066143     History of Changes
Other Study ID Numbers: 2009-P-001662
First Submitted: February 8, 2010
First Posted: February 10, 2010
Results First Submitted: April 7, 2017
Results First Posted: May 17, 2017
Last Update Posted: May 17, 2017
Last Verified: April 2017

Keywords provided by Igor Elman, MD, Mclean Hospital:
Seroquel
Generalized Anxiety Disorder
fMRI

Additional relevant MeSH terms:
Anxiety Disorders
Mental Disorders
Quetiapine Fumarate
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs